S&P 500   2,584.59 (-1.60%)
DOW   21,917.16 (-1.84%)
QQQ   190.40 (-0.85%)
AAPL   254.29 (-0.20%)
FB   166.80 (+0.51%)
MSFT   157.71 (-1.57%)
GOOGL   1,161.95 (+1.36%)
AMZN   1,949.72 (-0.72%)
CGC   14.42 (-0.28%)
NVDA   263.60 (-0.75%)
BABA   194.48 (+1.68%)
GE   7.94 (+0.63%)
TSLA   524.00 (+4.36%)
AMD   45.48 (-4.97%)
T   29.15 (-3.57%)
ACB   0.91 (+2.26%)
F   4.83 (-3.98%)
NFLX   375.50 (+1.22%)
BAC   21.23 (-3.68%)
GILD   74.76 (-1.54%)
PRI   88.48 (-2.46%)
DIS   96.60 (-3.21%)
S&P 500   2,584.59 (-1.60%)
DOW   21,917.16 (-1.84%)
QQQ   190.40 (-0.85%)
AAPL   254.29 (-0.20%)
FB   166.80 (+0.51%)
MSFT   157.71 (-1.57%)
GOOGL   1,161.95 (+1.36%)
AMZN   1,949.72 (-0.72%)
CGC   14.42 (-0.28%)
NVDA   263.60 (-0.75%)
BABA   194.48 (+1.68%)
GE   7.94 (+0.63%)
TSLA   524.00 (+4.36%)
AMD   45.48 (-4.97%)
T   29.15 (-3.57%)
ACB   0.91 (+2.26%)
F   4.83 (-3.98%)
NFLX   375.50 (+1.22%)
BAC   21.23 (-3.68%)
GILD   74.76 (-1.54%)
PRI   88.48 (-2.46%)
DIS   96.60 (-3.21%)
S&P 500   2,584.59 (-1.60%)
DOW   21,917.16 (-1.84%)
QQQ   190.40 (-0.85%)
AAPL   254.29 (-0.20%)
FB   166.80 (+0.51%)
MSFT   157.71 (-1.57%)
GOOGL   1,161.95 (+1.36%)
AMZN   1,949.72 (-0.72%)
CGC   14.42 (-0.28%)
NVDA   263.60 (-0.75%)
BABA   194.48 (+1.68%)
GE   7.94 (+0.63%)
TSLA   524.00 (+4.36%)
AMD   45.48 (-4.97%)
T   29.15 (-3.57%)
ACB   0.91 (+2.26%)
F   4.83 (-3.98%)
NFLX   375.50 (+1.22%)
BAC   21.23 (-3.68%)
GILD   74.76 (-1.54%)
PRI   88.48 (-2.46%)
DIS   96.60 (-3.21%)
S&P 500   2,584.59 (-1.60%)
DOW   21,917.16 (-1.84%)
QQQ   190.40 (-0.85%)
AAPL   254.29 (-0.20%)
FB   166.80 (+0.51%)
MSFT   157.71 (-1.57%)
GOOGL   1,161.95 (+1.36%)
AMZN   1,949.72 (-0.72%)
CGC   14.42 (-0.28%)
NVDA   263.60 (-0.75%)
BABA   194.48 (+1.68%)
GE   7.94 (+0.63%)
TSLA   524.00 (+4.36%)
AMD   45.48 (-4.97%)
T   29.15 (-3.57%)
ACB   0.91 (+2.26%)
F   4.83 (-3.98%)
NFLX   375.50 (+1.22%)
BAC   21.23 (-3.68%)
GILD   74.76 (-1.54%)
PRI   88.48 (-2.46%)
DIS   96.60 (-3.21%)
Log in

NASDAQ:AMGN - Amgen Stock Price, Forecast & News

$202.73
-5.75 (-2.76 %)
(As of 03/31/2020 04:00 PM ET)
Today's Range
$200.70
Now: $202.73
$207.25
50-Day Range
$182.24
MA: $208.92
$229.33
52-Week Range
$166.30
Now: $202.73
$244.99
Volume2.89 million shs
Average Volume4.66 million shs
Market Capitalization$119.57 billion
P/E Ratio15.75
Dividend Yield3.23%
Beta1.1
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells. It also markets other products in various markets, including Kyprolis, Nplate, Vectibix, Repatha, NEUPOGEN, Parsabiv, Blincyto, Aimovig, Imlygic, Corlanor, Kanjintitm, and Amgevitatm. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaborative agreements with Novartis; UCB; Bayer HealthCare Pharmaceuticals Inc.; and DaVita Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.
Read More
Amgen logo

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:AMGN
CUSIP03116210
Phone805-447-1000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$23.36 billion
Cash Flow$19.33 per share
Book Value$16.28 per share

Profitability

Net Income$7.84 billion

Miscellaneous

Employees23,400
Market Cap$119.57 billion
Next Earnings Date5/5/2020 (Estimated)
OptionableOptionable

Receive AMGN News and Ratings via Email

Sign-up to receive the latest news and ratings for AMGN and its competitors with MarketBeat's FREE daily newsletter.


Amgen (NASDAQ:AMGN) Frequently Asked Questions

How has Amgen's stock been impacted by COVID-19 (Coronavirus)?

Amgen's stock was trading at $198.65 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, AMGN shares have increased by 2.1% and is now trading at $202.73. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Amgen?

26 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amgen in the last year. There are currently 1 sell rating, 10 hold ratings and 15 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Amgen.

When is Amgen's next earnings date?

Amgen is scheduled to release its next quarterly earnings announcement on Tuesday, May 5th 2020. View our earnings forecast for Amgen.

How were Amgen's earnings last quarter?

Amgen, Inc. (NASDAQ:AMGN) posted its quarterly earnings data on Thursday, January, 30th. The medical research company reported $3.64 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $3.47 by $0.17. The medical research company earned $6.20 billion during the quarter, compared to the consensus estimate of $6.04 billion. Amgen had a return on equity of 85.52% and a net margin of 33.57%. The company's revenue was down .5% on a year-over-year basis. During the same period in the prior year, the company posted $3.42 EPS. View Amgen's earnings history.

How often does Amgen pay dividends? What is the dividend yield for Amgen?

Amgen declared a quarterly dividend on Wednesday, March 4th. Investors of record on Monday, May 18th will be given a dividend of $1.60 per share on Monday, June 8th. This represents a $6.40 dividend on an annualized basis and a yield of 3.16%. The ex-dividend date is Friday, May 15th. View Amgen's dividend history.

What guidance has Amgen issued on next quarter's earnings?

Amgen issued an update on its FY20 earnings guidance on Thursday, January, 30th. The company provided EPS guidance of $14.85-$15.60 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $16.10. The company issued revenue guidance of $25.0-$25.6 billion, compared to the consensus revenue estimate of $25.41 billion.

What price target have analysts set for AMGN?

26 analysts have issued 12-month price targets for Amgen's shares. Their forecasts range from $185.00 to $277.00. On average, they anticipate Amgen's share price to reach $239.64 in the next year. This suggests a possible upside of 18.2% from the stock's current price. View analysts' price targets for Amgen.

What are Wall Street analysts saying about Amgen stock?

Here are some recent quotes from research analysts about Amgen stock:
  • 1. William Blair analysts commented, "We ultimately view the deal as positive for Amgen and a good fit for management’s strategy given the low-risk nature of the deal and immediate accretion." (8/30/2019)
  • 2. Evercore ISI analysts commented, "We used a discount rate which is a function of cost of equity and cost of debt. Terminal growth rate estimates were used to derive future cash flows." (8/11/2019)
  • 3. According to Zacks Investment Research, "While Amgen’s newer drugs — Prolia, Xgeva, Blincyto, Kyprolis — will drive sales, biosimilar and brand competition faced by its legacy drugs will create pressure on the top line in 2019. Meanwhile, uptake of key drug, Repatha has been slow due to payer restrictions. However, Amgen is progressing well with its pipeline and approval of Aimovig was a huge boost. In the past five years, Amgen has launched nine products, including two in new therapeutic areas. Amgen boasts a strong biosimilars pipeline, which could be an important long-term growth driver for the company. Amgen’s restructuring plan is making it leaner and more cost efficient. Lower taxes and share buybacks should provide some support to the bottom line. Amgen’s shares have underperformed the industry this year so far. Estimates have declined lightly ahead of the Q1 earnings release. Amgen has a positive record of earnings surprises in recent quarters." (4/15/2019)
  • 4. Mizuho analysts commented, "We think the peak sales potential of Vascepa is underappreciated. Therefore, upward earnings revisions to levels not reflected in FactSet consensus expectations should drive AMRN shares higher. Valuation Summary We continue to use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12-month price target of $35." (4/12/2019)
  • 5. Cantor Fitzgerald analysts commented, ". We Reiterate our Neutral rating and $221 Price Target. We are attending the AACR (cancer research meeting) in Atlanta. Amgen presented its preclinical data for 24-minute session. The company’s molecule is targeting the KRAS p.G12C mutation and is a covalent inhibitor. The presentation explained how it identified a unique groove formed by rotation of an adjacent histidine residue (H95). An inactive form of KRAS reveals a small pocket P2 in GDP-KRAS, which is adjacent to cys12. The molecule binds to P2 and H95 and is expected to be dosed orally once daily. 510 has single-digit nanomolar potency and is 1,000x more selective to other KRAS mutants." (4/1/2019)

Has Amgen been receiving favorable news coverage?

News coverage about AMGN stock has trended positive recently, InfoTrie reports. InfoTrie identifies positive and negative media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Amgen earned a news impact score of 3.0 on InfoTrie's scale. They also gave media coverage about the medical research company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near future. View the latest news aboutAmgen.

Who are some of Amgen's key competitors?

What other stocks do shareholders of Amgen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amgen investors own include Johnson & Johnson (JNJ), Walt Disney (DIS), Alibaba Group (BABA), NVIDIA (NVDA), AT&T (T), Intel (INTC), Cisco Systems (CSCO), Pfizer (PFE), Home Depot (HD) and Gilead Sciences (GILD).

Who are Amgen's key executives?

Amgen's management team includes the following people:
  • Mr. Robert A. Bradway, Chairman, CEO & Pres (Age 56)
  • Mr. David W. Meline, Exec. VP & CFO (Age 62)
  • Mr. Jonathan P. Graham, Sr. VP, Gen. Counsel & Sec. (Age 58)
  • Dr. David M. Reese M.D., Exec. VP of R&D (Age 56)
  • Mr. Murdo Gordon, Exec. VP of Global Commercial Operations (Age 52)

What is Amgen's stock symbol?

Amgen trades on the NASDAQ under the ticker symbol "AMGN."

How do I buy shares of Amgen?

Shares of AMGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Amgen's stock price today?

One share of AMGN stock can currently be purchased for approximately $202.73.

How big of a company is Amgen?

Amgen has a market capitalization of $119.57 billion and generates $23.36 billion in revenue each year. The medical research company earns $7.84 billion in net income (profit) each year or $14.82 on an earnings per share basis. Amgen employs 23,400 workers across the globe. View additional information about Amgen.

What is Amgen's official website?

The official website for Amgen is http://www.amgen.com/.

How can I contact Amgen?

Amgen's mailing address is ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA, 91320. The medical research company can be reached via phone at 805-447-1000 or via email at [email protected]


MarketBeat Community Rating for Amgen (NASDAQ AMGN)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  1,382 (Vote Outperform)
Underperform Votes:  916 (Vote Underperform)
Total Votes:  2,298
MarketBeat's community ratings are surveys of what our community members think about Amgen and other stocks. Vote "Outperform" if you believe AMGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AMGN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/31/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel